Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Éric Pujade-Lauraine(Eau de Paris (France)), Bradley J. Monk(Florida Cancer Specialists & Research Institute), Radosław Mądry(Nordic Society of Gynecologic Oncology), Charles Anderson(Willamette Valley Cancer Institute and Research Center), Kan Yonemori(National Cancer Centre Japan), Alexandra Léary(Institut Gustave Roussy), Keiichi Fujiwara(Saitama Medical University), Samuel S. Dychter(Pfizer (United States)), Fabian Zohren(Pfizer (United States)), Kyung Hae Jung(University of Ulsan), Susana Banerjee(Royal Marsden NHS Foundation Trust), Amit M. Oza(Ontario Institute for Cancer Research), Anna V. Tinker(BC Cancer Agency), Jonathan A. Ledermann(London Cancer), Cristiana Sessa(Institute of Oncology Research), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Sang‐Yoon Park(National Cancer Center), Isabelle-Laure Ray-Coquard(Université Claude Bernard Lyon 1), Ross Stewart(AstraZeneca (United Kingdom)), Caimiao Wei(Pfizer (United States)), Gary Richardson(Cabrini Hospital)
Cited by 401
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k